US · Healthcare · Biotechnology
Analysts rate Telix Pharmaceuticals Limited a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $20.52.
| Fund | Stake |
|---|---|
| FMR Inc | 0.17% |
| Lazard Asset Management LLC | 0.08% |
| Manulife AIC Funds | 0.08% |
| Private Advisor Group, LLC | 0.06% |
| Marshall Wace Asset Management Ltd | 0.06% |
| Morgan Stanley - Brokerage Accounts | 0.05% |
| Integrated Wealth Concepts LLC | 0.05% |
| Hennion & Walsh Asset Management Inc | 0.04% |
| Document | Date |
|---|---|
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • On September 30, 2026, Telix Pharmaceuticals announced that the FDA granted Fast Track designation to BiPASS, its pre-biopsy prost | 2026-09-30 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Telix plans to acquire all outstanding equity securities of ITM Isotope Technologies Munich SE. • Upfront consideration: US$1.65B | 2026-09-21 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Telix Pharmaceuticals announced on September 14, 2026 that the U.S. Food and Drug Administration (FDA) approved Pixclara. BUSINES | 2026-09-14 |
| Current report (6-K) · Q3 2026 HEADLINE NUMBERS • Telix Pharmaceuticals reported completion of enrollment in its Phase 3 BiPASS study on September 2, 2026. • The company also stat | 2026-09-02 |
| Current report (6-K) · Q3 2026 OTHER NOTABLE POINTS • Telix Pharmaceuticals appointed David Gill as Chair, effective September 1, 2026. • The announcement was filed with the Austr | 2026-09-01 |
| Quarterly results (6-K) · Q2 2026 HEADLINE NUMBERS • Q2 2026 group revenue was US$247 million, up 7% quarter-over-quarter and 21% year-over-year. • Precision Medicine revenue was US$ | 2026-07-21 |
| Annual report FY2025 (20-F) HEADLINE NUMBERS • Telix Pharmaceuticals reported a $7.1 million loss after tax for the year ended December 31, 2025. • Net operating cash flow was | 2026-02-20 |
| Quarterly results (6-K) · Q3 2025 HEADLINE NUMBERS • Telix Pharmaceuticals reported US$206 million in revenue for the period covered by its October 14, 2025 announcement. • The compa | 2025-10-14 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Telix Pharmaceuticals Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.